Table 2.
Patient characteristics and outcomes distribution for the patients included in the study. 1yLC: Local control after 1 year since the end of the treatment.
| Number of Patients | |
|---|---|
| Age (range) | 69 (55–88) |
| Gender | |
| Female | 14 (40%) |
| Male | 21 (60%) |
| Histology | |
| Adenocarcinoma | 34 (97%) |
| Ductal Adenocarcinoma | 1 (3%) |
| Clinical Tumour Staging (T) | |
| cT1 | 2 (6%) |
| cT2 | 12 (34%) |
| cT3 | 8 (23%) |
| cT4 | 13 (37%) |
| Clinical Nodal Staging (N) | |
| cNx | 2 (6%) |
| cN0 | 20 (57%) |
| cN1 | 9 (25%) |
| cN2 | 2 (6%) |
| cN3 | 2 (6%) |
| Clinical Metastasis Staging (M) | |
| cM0 | 28 (80%) |
| cM1 | 7 (20%) |
| Structures Involved by Tumour at Diagnosis | |
| None | 2 (6%) |
| Duodenum | 1 (3%) |
| Pancreas | 11 (30%) |
| Liver | 2 (6%) |
| Vessels | 13 (37%) |
| Pancreas and Vessels | 2 (6%) |
| Duodenum and Vessels | 2 (6%) |
| Duodenum, Stomach and Vessels | 1 (3%) |
| Pancreas, Duodenum and Stomach | 1 (3%) |
| 1yLC | 20 (57%) |
| 1yOS | 24 (69%) |